Maxitrol is supplied as a sterile ointment in ... a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.

Attorney General Keith Ellison celebrates settlements with two drug companies he accused of “scheming” to raise prices on ...

Heritage Pharmaceuticals and Apotex will pay $49.1 million in a settlement with Pennsylvania, New Jersey and other states.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Hims & Hers Health (NYSE:HIMS) is gearing up to launch an off-patent version of Novo Nordisk's (NVO) (OTCPK:NONOF) older GLP-1 weight loss therapy liraglutide in 2025, CEO of the telehealth platform ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

Another colleague sees the agony in your face and offers to help. She offers you her generic acetaminophen bottle, and a part of you panics, thinking it might not be as effective as your cherished ...

Imbruvica (ibrutinib) is a prescription drug used to treat certain types of lymphoma, leukemia, and graft-versus-host disease. The cost of Imbruvica may depend on factors such as your dosage ...

Some North Carolinians may be eligible for compensation if they paid too much for generic prescription drugs made by Heritage ...

Find all the commercial and brand names of generic drug called Calcium Carbonate. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...

Your contributions will help us build the Web’s most valuable drug and treatments information resource. What are User Reviews and Ratings? WebMD's Drugs & Treatments database contains overviews ...

Lilly last week reported a rare $1.5 billion sales miss for its injectable obesity drug Zepbound and diabetes medicine Mounjaro combined, raising concerns among investors that demand might be cooling ...